NVO·Healthcare·Pharma
Novo Nordisk CagriSema -2.6%: Pipeline Shock and Price War
Novo Nordisk CagriSema flops in Phase 3, stock -2.6%: What does the study shock and price war for Wegovy and…
Healthcare
NVO·Healthcare·Pharma
FME.DE·Healthcare
Fresenius Medical Care Quarter -7.4%: Profit Jump, Cost-Cutting Program, but Outlook Shock
Fresenius Medical Care quarter with profit surge, strong cost-cutting program – but the cautious 2026 outlook significantly weighs on the…
HIMS·Healthcare
Hims & Hers Quarter Reports Revenue Boom and Forecast Shock
Hims & Hers quarter shows strong growth but weak outlook, GLP-1 dispute, and SEC risks – what this means for…
LLY·Healthcare·Pharma
Eli Lilly Weight Loss +5.2%: Rally Following Study Shock at Novo Nordisk
Eli Lilly Weight Loss: Stock jumps after weaker CagriSema data from Novo Nordisk – what does the rally mean for…
NVO·Healthcare·Pharma
Novo Nordisk CagriSema -15%: Study Shock Causes Stock Plunge
Novo Nordisk CagriSema misses against Tirzepatide in REDEFINE-4; stock plunges 15% in pre-market – what this means for investors.
MRK.DE·Healthcare
Merck Dividend Strategy Opportunity: Can It Withstand the Keytruda Patent Shock in 2028?
Merck dividend strategy in focus: Can the pipeline cushion the Keytruda patent cliff starting in 2028 for dividend hunters?